ClinicalTrials.gg
CompletedNCT05509400Updated Apr 21, 2026Results posted

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

A Phase 4 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 93 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
813
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
12th of 32
813 · median 618
Started
2022
with 7 others
Phase 4
9 of 32
4 open now
Registered
17th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 12th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 4, and was the 17th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).

Read the detailed description

This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease). Rimegepant will be further evaluated in this population with as needed use in a 12-week, open-label extension study.

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Acute Migraine
  • Headache
  • Acute treatment of Migraine in adults unsuitable for triptans
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
  • Migraine attacks, on average, lasting about 4 - 72 hours if untreated.
  • 4 to 14 migraine days per month on average across the 3 months prior to the Screening Visit (month is defined as 28 days for the purpose of this protocol).
  • Less than 15 headache days (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Phase.
  • Subjects must be able to distinguish migraine attacks from tension/cluster headaches.
  • Subjects on prophylactic migraine medication (excluding CGRP antagonists) are permitted to remain on therapy if they have been on a stable dose for at least 3 months (12 weeks) prior to the Screening Visit, and if the dose is not expected to change during the course of the study.
  • Triptan unsuitable

Exclusion criteria

Exclusion Criteria:

-Target Disease Exclusion:

  1. History of cluster headache, basilar migraine, or hemiplegic migraine
  2. Current medication overuse headaches
  3. Headaches occurring 15 or more days per month (migraine or non-migraine) in any of the 3 months prior to the Screening Visit
  4. Active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome [CRPS])
  5. Other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments of safety or efficacy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
813 participants (actual)

Study arms

  • Experimental
    Rimegepant

    Rimegepant - Double-blind (DB) Phase: One dose of rimegepant 75 mg Oral Disintegrating Tablet (ODT) Rimegepant/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT as needed for a qualifying acute migraine. A qualifying migraine is an attack of moderate or severe headache pain intensity. Migraine headache pain intensity will be measured on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe)

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    Placebo - Double-blind (DB) Phase: One dose of matching placebo Placebo/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT for a qualifying migraine

    Drug: Placebo · Drug: Rimegepant

Interventions

  • DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)

  • DrugPlacebo

    DB Phase: matching placebo

  • OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase

    Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain relief at 2 hours post-dose was defined as pain intensity of none or mild at that time point.

    Time frame: At 2 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Pain Freedom at 2 Hours Post-Dose: DBT Phase

    Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain freedom at 2 hours post-dose was a pain intensity of none at that time point.

    Time frame: At 2 hours post-dose

  2. Percentage of Participants Who Used Rescue Medications Within 24 Hours Post-Dose: DBT Phase

    Post 24 hours after dosing with study medication and after the 24-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: 1) non-steroidal anti-inflammatory drug like acetaminophen or aspirin, ibuprofen, naproxen; 2) antiemetics like metoclopramide, promethazine; 3) other like baclofen; 4) other approved pharmacological treatment with established efficacy in the acute treatment of migraine, including locally recognized standard of care, unless otherwise specified.

    Time frame: Within 24 hours post-dose

  3. Percentage of Participants With Return to Normal Function at 2 Hours Post-Dose: DBT Phase

    Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Return to normal function at 2 hours post-dose was defined as functional disability score of normal at that time point for participants with functional disability at the time of dosing.

    Time frame: At 2 hours post-dose

  4. Percentage of Participants With Sustained Return to Normal Function From 2 to 24 Hours Post-Dose: DBT Phase

    Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 24 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 24 hours post-dose in participants with functional disability at the time of dosing.

    Time frame: From 2 to 24 hours post-dose

  5. Percentage of Participants With Sustained Return to Normal Function From 2 to 48 Hours Post-Dose: DBT Phase

    Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 48 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 48 hours post-dose in participants with functional disability at the time of dosing.

    Time frame: From 2 to 48 hours post-dose

  6. Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose: DBT Phase

    Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 24 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 24 hours post-dose.

    Time frame: From 2 to 24 hours post-dose

  7. Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose: DBT Phase

    Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 48 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 48 hours post-dose.

    Time frame: From 2 to 48 hours post-dose

  8. Percentage of Participants With Sustained Freedom From Pain From 2 to 24 Hours Post-Dose: DBT Phase

    Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 24 hours post-dose was defined as a pain intensity of none at all time points from 2 to 24 hours post-dose.

    Time frame: From 2 to 24 hours post-dose

  9. Percentage of Participants With Sustained Freedom From Pain From 2 to 48 Hours Post-Dose: DBT Phase

    Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 48 hours post-dose was defined as a pain intensity of none at all time points from 2 to 48 hours post-dose.

    Time frame: From 2 to 48 hours post-dose

  10. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose: DBT Phase

    MBS freedom was defined as MBS reported before dosing that was absent post-dose at the specified time point. MBS reported before dosing was nausea, photophobia, or phonophobia. Each symptom (nausea, photophobia, or phonophobia) was measured post-dose using 0= absent or 1= present. Participants who had symptom score of 0 (absent) aligning with MBS reported before dosing were considered to have MBS freedom.

    Time frame: At 2 hours post-dose

  11. Reliability of Rimegepant Effect in the OLE Phase Based on Evaluable Qualifying Migraine Attacks (EQMA) of DBT and OLE Phase

    Reliability of rimegepant effect during OLE Phase achieved when difference between (1) percentage of participants randomized to rimegepant with response to single EQMA in DBT phase and(2) percentage of participants with response to \>=4 of first 5 EQMAs \>=23 hours(h) apart in OLE phase was \<=7%. Statistical analysis reports difference between (1) and (2) for each first 5 EQMAs \>=23h apart in OLE phase. Response: category of "moderately better" or"very much better" for Migraine Quality of Life Questionnaire(MQoL)Question(Q) 16 (overall change in migraine symptoms since taking study medication) at 24h post-dose. EQMA:evaluable qualifying migraine attack (migraine attack of moderate/severe pain intensity,first treated with rimegepant, not other acute headache medication) with nonmissing MQoL Q16 value at 24h post dose. Percentage of participants with response after single EQMA in DBT phase randomized to rimegepant and each of first 5 EQMA in OLE phase are reported in descriptive section.

    Time frame: DBT phase: up to maximum 45 days; OLE phase: up to maximum of 12 weeks

  12. Mean Change From Historical Baseline in Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase

    Mean change from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) at each specified month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history case report form (CRF). Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.

    Time frame: Baseline (3 months prior to Screening); Month 1 (OLE Days 1 to 28), Month 2 (OLE Days 29 to 56) and Month 3 (OLE Days 57 to 84), and Overall OLE phase (84 days)

  13. Percentage of Participants With at Least 50% Reduction From Historical Baseline in the Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase

    Percentages of participants with \>= 50% reduction from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) in each month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history CRF. Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.

    Time frame: Baseline (3 months prior to Screening); Month 1 (OLE Days 1 to 28), Month 2 (OLE Days 29 to 56) and Month 3 (OLE Days 57 to 84), and Overall OLE phase (84 days)

  14. Number of Participants With Adverse Events (AEs) by Intensity: DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.

    Time frame: DBT Phase: maximum of 45 days

  15. Number of Participants With Serious AEs: DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.

    Time frame: DBT Phase: maximum of 45 days

  16. Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.

    Time frame: DBT Phase: maximum of 45 days

  17. Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Abnormalities: DBT Phase

    Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.

    Time frame: DBT Phase: maximum of 45 days

  18. Number of Participants With AEs by Intensity: OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.

    Time frame: OLE Phase: maximum up to 12 weeks

  19. Number of Participants With Serious AEs: OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.

    Time frame: OLE Phase: maximum up to 12 weeks

  20. Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.

    Time frame: OLE Phase: maximum up to 12 weeks

  21. Number of Participants With On-Treatment Grade 3 to 4 Laboratory Abnormalities: OLE Phase

    Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.

    Time frame: OLE Phase: maximum up to 12 weeks

  22. Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Weeks 4, 8, and 12: OLE Phase

    MIBS was a 4-item self-administered questionnaire that measured interictal migraine related burden in the past 4 weeks on days when participants were not having an attack, using 4 domains: impairment in work or school; impairment in family and social life; difficulty making plans or commitments; emotional/affective and cognitive distress. The questionnaire specifically asked about the effect of the disease over the past 4 weeks on days without a headache attack. Response options included: don't know/not applicable (0), never (0), rarely (1), some of the time (2), much of the time (3), or most or all of the time (3). Each response associated with numerical score were summed across all 4 items resulting in a total MIBS score ranging from 0 to 12, and the level of interictal burden being categorized into the following: 0 for none and 12 for severe. Higher scores indicate worse interictal burden.

    Time frame: OLE phase: Baseline; Week 4, Week 8 and Week 12

07

Results

Posted Apr 21, 2026

Participant flow

A total of 813 participants were enrolled in the study, out of these 180 participants were not randomized. Only 633 participants were randomized. A total of 585 participants were treated with study intervention in double-blind treatment (DBT) phase. Then, 555 participants continued into open label extension (OLE) phase.

DBT Phase
Participant flow — DBT Phase
MilestoneDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Started317316
Treated295290
Completed286283
Not completed3133
Withdrew: Non-compliance with study drug42
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject47
Withdrew: Randomized but not treated1922
Withdrew: Lost to follow-up21
Withdrew: Physician decision01
OLE Phase
Participant flow — OLE Phase
MilestoneDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Started281274
Treated281271
Completed265254
Not completed1620
Withdrew: Adverse event32
Withdrew: Lost to follow-up02
Withdrew: Other32
Withdrew: Physician decision20
Withdrew: Pregnancy01
Withdrew: Protocol violation30
Withdrew: Withdrawal by subject511
Withdrew: Failure to meet continuation criteria02

Outcome measures

PrimaryPercentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase

Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain relief at 2 hours post-dose was defined as pain intensity of none or mild at that time point.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase55.9 (50.2 to 61.7)32.7 (27.3 to 38.2)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 · Difference in percentages: 23.2 · 95% CI 15.3 to 31.1
SecondaryPercentage of Participants With Pain Freedom at 2 Hours Post-Dose: DBT Phase

Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain freedom at 2 hours post-dose was a pain intensity of none at that time point.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Freedom at 2 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Pain Freedom at 2 Hours Post-Dose: DBT Phase22.7 (17.9 to 27.6)7.4 (4.4 to 10.4)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 (Tested in hierarchical order.) · Difference in percentages: 15.3 · 95% CI 9.6 to 21.1
SecondaryPercentage of Participants Who Used Rescue Medications Within 24 Hours Post-Dose: DBT Phase

Post 24 hours after dosing with study medication and after the 24-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: 1) non-steroidal anti-inflammatory drug like acetaminophen or aspirin, ibuprofen, naproxen; 2) antiemetics like metoclopramide, promethazine; 3) other like baclofen; 4) other approved pharmacological treatment with established efficacy in the acute treatment of migraine, including locally recognized standard of care, unless otherwise specified.

Time frame:
Within 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Used Rescue Medications Within 24 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants Who Used Rescue Medications Within 24 Hours Post-Dose: DBT Phase18.0 (13.5 to 22.5)46.2 (40.4 to 52.1)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 (Tested in hierarchical order.) · Difference in percentages: -28.2 · 95% CI -35.6 to -20.8
SecondaryPercentage of Participants With Return to Normal Function at 2 Hours Post-Dose: DBT Phase

Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Return to normal function at 2 hours post-dose was defined as functional disability score of normal at that time point for participants with functional disability at the time of dosing.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Return to Normal Function at 2 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Return to Normal Function at 2 Hours Post-Dose: DBT Phase28.9 (23.0 to 34.7)12.7 (8.4 to 16.9)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 (Tested in hierarchical order.) · Difference in percentages: 16.2 · 95% CI 9.0 to 23.4
SecondaryPercentage of Participants With Sustained Return to Normal Function From 2 to 24 Hours Post-Dose: DBT Phase

Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 24 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 24 hours post-dose in participants with functional disability at the time of dosing.

Time frame:
From 2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Return to Normal Function From 2 to 24 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Sustained Return to Normal Function From 2 to 24 Hours Post-Dose: DBT Phase18.1 (13.1 to 23.1)6.8 (3.6 to 9.9)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = 0.0002 (Tested in hierarchical order.) · Difference in percentages: 11.4 · 95% CI 5.5 to 17.2
SecondaryPercentage of Participants With Sustained Return to Normal Function From 2 to 48 Hours Post-Dose: DBT Phase

Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 48 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 48 hours post-dose in participants with functional disability at the time of dosing.

Time frame:
From 2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Return to Normal Function From 2 to 48 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Sustained Return to Normal Function From 2 to 48 Hours Post-Dose: DBT Phase15.9 (11.2 to 20.7)4.2 (1.7 to 6.8)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 (Tested in hierarchical order.) · Difference in percentages: 11.7 · 95% CI 6.4 to 17.1
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose: DBT Phase

Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 24 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 24 hours post-dose.

Time frame:
From 2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose: DBT Phase38.8 (33.2 to 44.5)14.4 (10.3 to 18.5)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 (Tested in hierarchical order.) · Difference in percentages: 24.4 · 95% CI 17.4 to 31.3
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose: DBT Phase

Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 48 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 48 hours post-dose.

Time frame:
From 2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose: DBT Phase33.9 (28.4 to 39.4)10.6 (7.0 to 14.1)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 (Tested in hierarchical order.) · Difference in percentages: 23.4 · 95% CI 16.8 to 29.9
SecondaryPercentage of Participants With Sustained Freedom From Pain From 2 to 24 Hours Post-Dose: DBT Phase

Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 24 hours post-dose was defined as a pain intensity of none at all time points from 2 to 24 hours post-dose.

Time frame:
From 2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Freedom From Pain From 2 to 24 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Sustained Freedom From Pain From 2 to 24 Hours Post-Dose: DBT Phase14.0 (10.0 to 18.0)4.9 (2.4 to 7.4)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = 0.0002 (Tested in hierarchical order.) · Difference in percentages: 9.1 · 95% CI 4.3 to 13.8
SecondaryPercentage of Participants With Sustained Freedom From Pain From 2 to 48 Hours Post-Dose: DBT Phase

Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 48 hours post-dose was defined as a pain intensity of none at all time points from 2 to 48 hours post-dose.

Time frame:
From 2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Freedom From Pain From 2 to 48 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Sustained Freedom From Pain From 2 to 48 Hours Post-Dose: DBT Phase12.2 (8.4 to 16.0)2.8 (0.9 to 4.7)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = <0.0001 (Tested in hierarchical order.) · Difference in percentages: 9.4 · 95% CI 5.2 to 13.7
SecondaryPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose: DBT Phase

MBS freedom was defined as MBS reported before dosing that was absent post-dose at the specified time point. MBS reported before dosing was nausea, photophobia, or phonophobia. Each symptom (nausea, photophobia, or phonophobia) was measured post-dose using 0= absent or 1= present. Participants who had symptom score of 0 (absent) aligning with MBS reported before dosing were considered to have MBS freedom.

Time frame:
At 2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose: DBT Phase
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose: DBT Phase31.1 (25.8 to 36.5)18.7 (14.1 to 23.2)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Crude risk estimation · p = 0.0005 (Tested in hierarchical order.) · Difference in percentages: 12.5 · 95% CI 5.4 to 19.5
SecondaryReliability of Rimegepant Effect in the OLE Phase Based on Evaluable Qualifying Migraine Attacks (EQMA) of DBT and OLE Phase

Reliability of rimegepant effect during OLE Phase achieved when difference between (1) percentage of participants randomized to rimegepant with response to single EQMA in DBT phase and(2) percentage of participants with response to \>=4 of first 5 EQMAs \>=23 hours(h) apart in OLE phase was \<=7%. Statistical analysis reports difference between (1) and (2) for each first 5 EQMAs \>=23h apart in OLE phase. Response: category of "moderately better" or"very much better" for Migraine Quality of Life Questionnaire(MQoL)Question(Q) 16 (overall change in migraine symptoms since taking study medication) at 24h post-dose. EQMA:evaluable qualifying migraine attack (migraine attack of moderate/severe pain intensity,first treated with rimegepant, not other acute headache medication) with nonmissing MQoL Q16 value at 24h post dose. Percentage of participants with response after single EQMA in DBT phase randomized to rimegepant and each of first 5 EQMA in OLE phase are reported in descriptive section.

Time frame:
DBT phase: up to maximum 45 days; OLE phase: up to maximum of 12 weeks
Reported as:
Number · Percentage of participants
Reliability of Rimegepant Effect in the OLE Phase Based on Evaluable Qualifying Migraine Attacks (EQMA) of DBT and OLE Phase
Percentage of participantsDB RimegepantOL Rimegepant
DBT Phase EQMA64.2 (58.2 to 70.2)—
OLE Phase First EQMA—65.1 (61.0 to 69.2)
OLE Phase Second EQMA—66.9 (62.8 to 71.0)
OLE Phase Third EQMA—69.1 (65.0 to 73.2)
OLE Phase Fourth EQMA—70.8 (66.5 to 75.0)
OLE Phase Fifth EQMA—71.1 (66.3 to 75.8)
Statistical analysis
  • DB Rimegepant vs OL Rimegepant · Difference in percentages: -0.9
  • DB Rimegepant vs OL Rimegepant · Difference in percentages: -2.7
  • DB Rimegepant vs OL Rimegepant · Difference in percentages: -4.9
  • DB Rimegepant vs OL Rimegepant · Difference in percentages: -6.6
  • DB Rimegepant vs OL Rimegepant · Difference in percentages: -6.9
SecondaryMean Change From Historical Baseline in Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase

Mean change from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) at each specified month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history case report form (CRF). Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.

Time frame:
Baseline (3 months prior to Screening); Month 1 (OLE Days 1 to 28), Month 2 (OLE Days 29 to 56) and Month 3 (OLE Days 57 to 84), and Overall OLE phase (84 days)
Reported as:
Mean · Migraine days per month
Mean Change From Historical Baseline in Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase
Migraine days per monthDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Total historical baseline7.8 ± 2.567.8 ± 2.57
Total: Change at Month 1-3.3 ± 3.51-3.6 ± 3.45
Total: Change at Month 2-2.3 ± 3.74-2.7 ± 3.81
Total: Change at Month 3-2.1 ± 3.76-2.5 ± 4.01
Total: Change in overall OLE phase-2.6 ± 3.31-3.0 ± 3.37
Moderate or severe historical baseline6.7 ± 2.446.6 ± 2.56
Moderate or severe: Change at Month 1-2.4 ± 3.63-2.6 ± 3.49
Moderate or severe: Change at Month 2-1.3 ± 4.00-1.7 ± 3.79
Moderate or severe: Change at Month 3-1.0 ± 4.02-1.5 ± 4.09
Moderate or severe: Change in overall OLE phase-1.6 ± 3.57-1.9 ± 3.40
SecondaryPercentage of Participants With at Least 50% Reduction From Historical Baseline in the Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase

Percentages of participants with \>= 50% reduction from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) in each month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history CRF. Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.

Time frame:
Baseline (3 months prior to Screening); Month 1 (OLE Days 1 to 28), Month 2 (OLE Days 29 to 56) and Month 3 (OLE Days 57 to 84), and Overall OLE phase (84 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 50% Reduction From Historical Baseline in the Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase
Percentage of participantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Total: Change at Month 150.757.9
Total: Change at Month 242.143.3
Total: Change at Month 340.542.2
Total: Change in overall OLE phase36.241.7
Moderate or severe: Change at Month 147.549.6
Moderate or severe: Change at Month 237.337.5
Moderate or severe: Change at Month 332.435.9
Moderate or severe: Change in overall OLE phase33.735.0
SecondaryNumber of Participants With Adverse Events (AEs) by Intensity: DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.

Time frame:
DBT Phase: maximum of 45 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) by Intensity: DBT Phase
ParticipantsDB RimegepantDB Placebo
Mild31 (25.8 to 36.5)19 (14.1 to 23.2)
Moderate615
Severe01
SecondaryNumber of Participants With Serious AEs: DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.

Time frame:
DBT Phase: maximum of 45 days
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs: DBT Phase
ParticipantsDB RimegepantDB Placebo
Number of Participants With Serious AEs: DBT Phase0 (25.8 to 36.5)0 (14.1 to 23.2)
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.

Time frame:
DBT Phase: maximum of 45 days
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase
ParticipantsDB RimegepantDB Placebo
Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase0 (25.8 to 36.5)0 (14.1 to 23.2)
SecondaryNumber of Participants With Any On-Treatment Grade 3 to 4 Laboratory Abnormalities: DBT Phase

Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.

Time frame:
DBT Phase: maximum of 45 days
Reported as:
Count of participants · Participants
Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Abnormalities: DBT Phase
ParticipantsDB RimegepantDB Placebo
Eosinophils, high00
Hemoglobin, high00
Hemoglobin, low00
Leukocytes, low00
Lymphocytes, high00
Lymphocytes, low00
Neutrophils, low00
Platelets, low00
Alanine Aminotransferase, high00
Alkaline Phosphatase, high00
Aspartate Aminotransferase, high00
Bicarbonate, low00
Bilirubin, high00
Creatinine, high00
Glucose, high00
Glucose, low00
Potassium, high0 (25.8 to 36.5)1 (14.1 to 23.2)
Potassium, low00
Sodium, high00
Sodium, low00
SecondaryNumber of Participants With AEs by Intensity: OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.

Time frame:
OLE Phase: maximum up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs by Intensity: OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Mild9786
Moderate6553
Severe12
SecondaryNumber of Participants With Serious AEs: OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.

Time frame:
OLE Phase: maximum up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs: OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Number of Participants With Serious AEs: OLE Phase11
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.

Time frame:
OLE Phase: maximum up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase32
SecondaryNumber of Participants With On-Treatment Grade 3 to 4 Laboratory Abnormalities: OLE Phase

Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.

Time frame:
OLE Phase: maximum up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With On-Treatment Grade 3 to 4 Laboratory Abnormalities: OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Eosinophils, high00
Hemoglobin, high00
Hemoglobin, low00
Leukocytes, low10
Lymphocytes, high00
Lymphocytes, low10
Neutrophils, low30
Platelets, low00
Alanine Aminotransferase, high00
Alkaline Phosphatase, high00
Aspartate Aminotransferase, high00
Bicarbonate, low00
Bilirubin, high00
Creatinine, high00
Glucose, high10
Glucose, low00
Potassium, high00
Potassium, low00
Sodium, high00
Sodium, low00
SecondaryMean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Weeks 4, 8, and 12: OLE Phase

MIBS was a 4-item self-administered questionnaire that measured interictal migraine related burden in the past 4 weeks on days when participants were not having an attack, using 4 domains: impairment in work or school; impairment in family and social life; difficulty making plans or commitments; emotional/affective and cognitive distress. The questionnaire specifically asked about the effect of the disease over the past 4 weeks on days without a headache attack. Response options included: don't know/not applicable (0), never (0), rarely (1), some of the time (2), much of the time (3), or most or all of the time (3). Each response associated with numerical score were summed across all 4 items resulting in a total MIBS score ranging from 0 to 12, and the level of interictal burden being categorized into the following: 0 for none and 12 for severe. Higher scores indicate worse interictal burden.

Time frame:
OLE phase: Baseline; Week 4, Week 8 and Week 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Weeks 4, 8, and 12: OLE Phase
Scores on a scaleDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Change at week 4-0.8 ± 3.01-1.1 ± 3.02
Change at week 8-1.0 ± 3.17-1.3 ± 3.04
Change at week 12-1.1 ± 3.28-1.5 ± 3.46

Adverse events

Collected over DBT Phase: maximum of 45 days; OLE Phase: maximum up to 12 weeks; Follow-up phase: 2 weeks after the discontinuation or completion of the OLE phase; Post-DBT Pre-OLE (Interim) phase: OL rimegepant start date - DB study drug date > 9 days (up to 13 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Rimegepant: DBT Phase0/295 (0%)0/295 (0%)116/295 (39.3%)
DB Placebo: DBT Phase0/290 (0%)0/290 (0%)20/290 (6.9%)
DB Rimegepant/OL Rimegepant: Post-DBT Pre-OLE Phase0/253 (0%)0/253 (0%)0/253 (0%)
DB Placebo/OL Rimegepant: Post-DBT Pre-OLE Phase0/244 (0%)0/244 (0%)0/244 (0%)
DB Rimegepant/ OL Rimegepant: OLE Phase0/281 (0%)1/281 (0.4%)68/281 (24.2%)
DB Placebo/ OL Rimegepant: OLE Phase0/271 (0%)1/271 (0.4%)56/271 (20.7%)
DB Rimegepant/ OL Rimegepant: Follow-up Phase0/283 (0%)1/283 (0.4%)67/283 (23.7%)
DB Placebo/ OL Rimegepant: Follow-up Phase0/267 (0%)2/267 (0.7%)55/267 (20.6%)
Most frequent serious events
Most frequent serious events
EventDB Rimegepant: DBT PhaseDB Placebo: DBT PhaseDB Rimegepant/OL Rimegepant: Post-DBT Pre-OLE PhaseDB Placebo/OL Rimegepant: Post-DBT Pre-OLE PhaseDB Rimegepant/ OL Rimegepant: OLE PhaseDB Placebo/ OL Rimegepant: OLE PhaseDB Rimegepant/ OL Rimegepant: Follow-up PhaseDB Placebo/ OL Rimegepant: Follow-up Phase
Abdominal pain upperGastrointestinal disorders0/2950/2900/2530/2440/2810/2710/2831/267
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/2950/2900/2530/2441/2810/2711/2831/267
Suicidal IdeationPsychiatric disorders0/2950/2900/2530/2440/2811/2710/2830/267
Most frequent other events
Most frequent other events
EventDB Rimegepant: DBT PhaseDB Placebo: DBT PhaseDB Rimegepant/OL Rimegepant: Post-DBT Pre-OLE PhaseDB Placebo/OL Rimegepant: Post-DBT Pre-OLE PhaseDB Rimegepant/ OL Rimegepant: OLE PhaseDB Placebo/ OL Rimegepant: OLE PhaseDB Rimegepant/ OL Rimegepant: Follow-up PhaseDB Placebo/ OL Rimegepant: Follow-up Phase
NasopharyngitisInfections and infestations72/29511/2900/2530/24444/28136/27143/28335/267
Upper respiratory tract infectionInfections and infestations29/2951/2900/2530/24418/28112/27118/28312/267
HeadacheNervous system disorders27/29510/2900/2530/24416/28117/27116/28317/267

Baseline characteristics

Safety analysis set (SAS) included participants in the enrolled analysis set who took \>= 1 dose of study drug. Enrolled analysis set included participants who signed an informed consent form and were assigned a participant identification number, i.e., non-missing informed consent date.

Age, Continuous
Age, Continuous(Years)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
Mean43.0 ± 11.7942.7 ± 11.5042.9 ± 11.64
Sex: Female, Male
Sex: Female, Male(Participants)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
Female260261521
Male352964
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
White534598
Black or African American5813
Multiracial011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
Hispanic or Latino7815
Not Hispanic or Latino504696
08

Study locations

93 sites
  • Clinical Research Institute
    Los Angeles, California 90048, United States
  • Ki Health Partners LLC, dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Wr-Msra, Llc
    Lake City, Florida 32055, United States
  • Sensible Healthcare LLC
    Ocoee, Florida 34761, United States
  • Sandhill Research, LLC d/b/a Accel Research Sites Network - Ormond Clinical Research Unit
    Ormond Beach, Florida 32174, United States
  • WR-Mount Vernon Clinical Research, LLC
    Sandy Springs, Georgia 30328, United States
  • Collective Medical Research
    Overland Park, Kansas 66210, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Community Clinical Research Network Inc
    Marlborough, Massachusetts 01752, United States
  • Michigan Headache & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Rochester Medical Group
    Rochester Hills, Michigan 48307, United States
  • DM Clinical Research - Detroit
    Southfield, Michigan 48076, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65807, United States
  • St Charles Clinical Research
    Weldon Spring, Missouri 63304, United States
  • DM Clinical Research - NY, NY
    Brooklyn, New York 11220, United States
  • New York Neurology Associates
    New York, New York 10003, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Headache Wellness Center, PC
    Greensboro, North Carolina 27405, United States
  • Synexus Clinical Research US, Inc. - Anderson
    Anderson, South Carolina 29621, United States
  • Red Star Research, LLC
    Lake Jackson, Texas 77566, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • USC Clinical Trials Centre
    Sippy Downs, Queensland 4556, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Klinikum Klagenfurt am Wörthersee
    Klagenfurt, Carinthia 9020, Austria
  • Medical University Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • Cabinet Privé Dr. Simona Sava
    Saint-Nicolas, Liège 4420, Belgium
  • GZA Ziekenhuizen
    Antwerp, 2610, Belgium
  • UZ Brussel
    Brussels, 1090, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
  • University of Calgary South Health Campus
    Calgary, Alberta T3M 1M4, Canada
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T 0G1, Canada
  • Clinique Neuro-Lévis
    Lévis, Quebec G6W 0M5, Canada
  • Alpha Recherche Clinique
    Québec, Quebec G3K 2P8, Canada
  • ALPHA Recherche Clinique
    Québec, G2J 0C4, Canada
  • University Hospital of Southern Denmark
    Esbjerg, DK-6700, Denmark
  • Danish Headache Center
    Glostrup Municipality, 2600, Denmark
  • Hospitalsenhed Midt
    Viborg, DK-8800, Denmark
  • Helsinki Headache Center
    Helsinki, Uusimaa 00830, Finland
  • Terveystalo Ruoholahti
    Helsinki, Finland
  • Terveystalo Tampere Rautatienkatu
    Tampere, 33100, Finland
  • Terveystalo Pulssi
    Turku, 20100, Finland
  • Timone Hospital
    Marseille, Provence 13005, France
  • Hospices Civils de Lyon - Hôpital Neurologique Pierre Wertheimer
    Bron, 69500, France
  • CHU Clermont Ferrand - Hopital Gabriel Montpied
    Clermont-Ferrand, 63000, France
  • Centre Hospitalier Annecy Genevois
    Epagny Metz-Tessy, 74370, France
  • CHU de Lille - Hôpital Salengro
    Lille, 59037, France
  • CHU Nice Hopital Cimiez
    Nice, 06000, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • CHU Saint-Etienne - Hopital Nord
    Saint-Etienne, 42055, France
  • Neurologische Praxis Prof. Dr. Hartmut Gobel
    Kiel, Schleswig-Holstein D-24149, Germany
  • University Hospital Jena
    Jena, Thuringia 07747, Germany
  • Charité Universitätsmedizin Berlin, Neurologische Ambulanz, Kopfschmerzambulanz
    Berlin, 10117, Germany
  • Kopfschmerzzentrum Frankfurt
    Frankfurt, 65929, Germany
  • IRCCS Ospedale San Raffaele
    Milan, MI 20132, Italy
  • AOU Luigi Vanvitelli
    Naples, Naples 80138, Italy
  • Fondazione Policlinico Campus BioMedico
    Rome, RM 00128, Italy
  • Foundation IRCCS Neurological Institute Carlo Besta
    Milan, 20133, Italy
  • AOU Policlinico di Modena
    Modena, 41124, Italy
  • Fondazione Mondino - Istituto Neurologico Nazionale IRCCS
    Pavia, 27100, Italy
  • Headache and Pain Unit - IRCCS San Raffaele
    Rome, 00163, Italy
  • Clinical Research Institute S.C.
    Tlalnepantla, State of Mexico 54055, Mexico
  • Centro de Investigación Médica de Aguascalientes (CIMA)
    Aguascalientes, 20116, Mexico
  • Operadora Unidad de Investigación En Salud de Chihuahua, Sa de Cv
    Mexico City, 14050, Mexico
  • Clinstile SA de CV
    Mexico City, CDMX 06700, Mexico
  • Centrum Medyczne Neuromed
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-163, Poland
  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
    Wroclaw, Lower Silesian Voivodeship 52-210, Poland
  • Twoja Przychodnia Nowosolskie Centrum Medyczne
    Nowa Sól, Lubusz Voivodeship 67-100, Poland
  • Concept Medica
    Warsaw, Masovian Voivodeship 00-773, Poland
  • MICS Centrum Medyczne Damiana Walbrzyska
    Warsaw, Masovian Voivodeship 02-739, Poland
  • Instytut Zdrowia dr Boczarska-Jedynak Sp. z o.o. Sp. k.
    Oświęcim, Małopolska 32-600, Poland
  • Vita Longa Sp. Z o.o.
    Katowice, 40-748, Poland
  • MICS Centrum Medyczne Szczecin
    Szczecin, 70-784, Poland
  • Praktyka Lekarska
    Warsaw, 00-144, Poland
  • MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
  • Centrum Leczenia Bolu dr n med Lukasz Kmieciak
    Lodz, Łódź Voivodeship 91-363, Poland
  • University Hospital Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Virgen del Rocio University Hospital
    Seville, 41013, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • CTC Solna
    Solna, Stockholms LÄN [se-01] 171 64, Sweden
  • CTC Uppsala
    Uppsala, Uppsala County 752 37, Sweden
  • Skåneuro Privatmottagning
    Lund, 222 22, Sweden
  • Hälsoklustret
    Stockholm, 112 39, Sweden
  • Akardo MedSite
    Stockholm, 117 27, Sweden
  • Re: Cognition Health Ltd.
    Edgebaston, Birmingham B16 8LT, United Kingdom
  • 4 Medical Clinical Solutions London
    Ilford, Essex IG1 4HP, United Kingdom
  • Lakeside Healthcare Group Research
    Corby, Northamptonshire NN17 2UR, United Kingdom
  • Kings College London
    London, WC2R 2LS, United Kingdom
  • 4 Medical Clinical Solutions
    Swinton, M27 8FF, United Kingdom
09

References and documents

Publications

  • Ashina M, McAllister P, Gaul C, Leyva-Rendon A, Ramirez LM, Nalpas C, Thiry A, Abraham L, Fountaine RJ, Fullerton T. Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study. Pain Manag. 2026 Jun;16(6):551-565. doi: 10.1080/17581869.2026.2646705. Epub 2026 Apr 3. PubMed 41930741 ↗
  • Ashina M, McAllister P, Gaul C, Leyva-Rendon A, Ramirez LM, Nalpas C, Thiry A, Abraham L, Fountaine RJ, Fullerton T. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial. Cephalalgia. 2025 Nov;45(11):3331024251395298. doi: 10.1177/03331024251395298. Epub 2025 Nov 18. PubMed 41255093 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Mar 2025, 28 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 28 months is close to that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2022
First posted
Aug 22, 2022
StartActual
Oct 18, 2022
Primary completionActual
Mar 10, 2025
CompletionActual
Jun 10, 2025
Results first posted
Apr 21, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05509400
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Oct 18, 2022
Primary completion
Mar 10, 2025
Completion
Jun 10, 2025
Results posted
Apr 21, 2026
Last update
Apr 21, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion